I
nterleukin-11 is a 20-kDa stromal cell-derived pleiotropic cytokine that interacts with a variety of hemopoietic and nonhemopoietic cell types. Recombinant human IL-11 stimulates megakaryocytopoiesis in vitro (1) and in vivo (2) . It also stimulates erythropoiesis and regulates macrophage proliferation and differentiation (3) . Due to its thrombopoietic activities in vivo, IL-11 is used to treat chemotherapy-induced thrombocytopenia (4) .
In addition to its hemopoietic activities, IL-11 protects against various forms of mucosal injury. These effects are most extensively described in the gastrointestinal tract of rodents where IL-11 protects small intestinal cells from combined radiation, chemotherapy, and ischemia in mice (5-7); reduces experimental colitis induced by trinitrobenzenesulfonic acid in rats (8) ; and ameliorates inflammatory bowel disease in mice (6) . In these studies, treatment with IL-11 not only decreased mucosal damage but also accelerated healing and improved survival. IL-11 also reduces immunemediated small bowel injury in acute graft-vs-host disease after murine allogeneic bone marrow transplantation (9) .
The protective effects of IL-11 are not restricted to the intestine because IL-11 has also been shown to improve survival after thoracic irradiation (10) . Human IL-11, expressed as a transgene in bronchial mucosa, reduces mortality associated with hyperoxia in mice (11) . This effect was associated with a reduction in multiple parameters of lung injury including alveolar-capillary protein leak, endothelial cell (EC) 4 and epithelial cell membrane injury, lipid peroxidation, pulmonary neutrophil recruitment, IL-12 and TNF production, and DNA fragmentation.
The mechanism(s) by which IL-11 protects mucosae are not completely understood. Both antiinflammatory and direct cytoprotective effects of IL-11 could contribute to the reduction of injury. IL-11 may exert antiinflammatory effects by reducing cytokine production by macrophages (12) (13) (14) . It also may promote immune deviation from a T H 1-like to a T H 2-like phenotype, which may ameliorate some types of immune-mediated injury (9) . To date, there have been no reports of direct cytoprotection in cultured cells.
Direct cytoprotection would likely involve the induction of specific gene products. IL-11 belongs to the IL-6 family of cytokines, all of which use gp130 as a critical component for signal transduction (15) (16) (17) . IL-11 initiates signaling via binding to a unique IL-11-receptor-␣ (IL-11R␣) chain (18, 19) . The IL-11/IL-11R␣ complex is thought to bind to and induce clustering of gp130, leading to the activation, via transphosphorylation, of associated Janus kinases (JAKs) (20, 21) . Activated JAKs phosphorylate tyrosine residues within the cytoplasmic region of gp130 which then serve as docking sites for STAT3 and STAT1 proteins (22, 23) . The activated JAKs subsequently phosphorylate tyrosine residues within the bound STAT proteins, causing the STATs to dissociate from gp130, dimerize (24) , and enter the nucleus to act as transcriptional activators of target genes (25, 26) . STAT dimers may be additionally phosphorylated on serine or threonine residues by mitogen-activated protein kinases (MAPKs) (27, 28) that are also activated in response to cytokine binding to the receptor (29, 30) . This additional phosphorylation may potentiate STAT function as an activator of transcription.
Immune and inflammatory processes depend on cytokine-mediated activation of vascular endothelium (e.g., new adhesion molecule expression via an NF-B-dependent process) (31) and often injure vascular endothelium, resulting in additional epithelial injury as a consequence of ischemia which follows endothelial damage. Therefore, we investigated whether IL-11 could act on cultured HUVECs to inhibit proinflammatory functions or to induce cytoprotection. We report here that HUVECs express functional IL-11 receptors and respond to IL-11 by activating both STAT and MAPK signaling pathways. Pretreatment of HUVECs with low dose IL-11 can protect HUVECs from immune-mediated injury, measured as cytolytic CTL-or Ab plus C-mediated lysis, but did not inhibit TNF-induced activation of NF-B or expression of leukocyte adhesion molecules.
Materials and Methods

Cytokines, drugs, and Abs and other reagents
Recombinant human IL-11, neutralizing mouse mAb to IL-11, and three different mouse mAbs to IL-11R␣-chain were provided by Genetics Institute (Andover, MA). Recombinant human oncostatin M and recombinant human IFN-␥ were purchased from R&D Systems (Minneapolis, MN). Recombinant human TNF was a gift from Biogen (Cambridge, MA). Fibroblast growth factor-1, commonly called endothelial cell growth supplement (ECGS), was obtained from Collaborative Research/Becton Dickinson (Bedford, MA) and used in conjunction with porcine intestinal heparin (Sigma, St. Louis, MO). The pharmacological inhibitor of mitogen-activated protein/extracellular signal-related kinase kinase (MEK-1) (PD98059) was obtained from Calbiochem (La Jolla, CA), and the protein synthesis inhibitor cycloheximide was obtained from Sigma. Rabbit polyclonal Abs reactive with STAT1, phosphotyrosine-STAT1, STAT3, phosphotyrosine-STAT3, p42, and p44 MAPK and phosphothreonine/phosphotyrosine p42 and p44 MAPK were purchased from New England Biolabs (Beverly, MA). Rabbit polyclonal Ab to gp130 and mouse mAb to phosphotyrosine were purchased from Upstate Biotechnology (Lake Placid, NY). Rabbit polyclonal Ab to I-B␣ was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-class I MHC mAb (W6/32) was prepared as ascites in our laboratory from a clone provided by Dr. Jack Strominger (Harvard University, Cambridge, MA), and FITC-conjugated anti-class I MHC mAb (W6/32) was purchased from Serotech (Oxford, U.K.). Mouse anti-E-selectin mAb (clone H14/18) and nonbinding (K16/ 16) Ab were made as ascites in our laboratory. Mouse anti-ICAM-1 mAb (2D5) was a gift from Dr. Dario Altieri (Yale University, New Haven, CT). FITC-conjugated polyclonal goat anti-mouse Ab was purchased from Boehringer Mannheim (Indianapolis, IN). Baby rabbit C was purchased from Pel-Freez (Brown Dear, WI).
Cell isolation and culture
Human EC were isolated from umbilical veins as previously described (32, 33) and cultured on gelatin (J. T. Baker, Phillipsburg, NJ)-coated tissue culture plastic at 37°C in 5% CO 2, humidified air in Medium 199 containing 20% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin (all from Life Technologies, Grand Island, NY), 50 g/ml ECGS and 100 g/ml porcine intestinal heparin. K562 and CACO-2 cells were obtained from the American Type Culture Collection (Rockville, MD; accession number for K562, CCL-243) and cultured at 37°C in 5% CO 2 -humidified air in RPMI 1640 (Life Technologies) containing 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin.
RNase protection assay
RNA was harvested from HUVECs, K562 cells, and CACO-2 cells using an RNeasy kit (Qiagen, Santa Clarita, CA), and 4 g of each RNA were incubated with a 32 P-labeled probe cocktail against human-IL-11R␣-chain and GAPDH as loading control (Riboquant kit and custom template, PharMingen, San Diego, CA). Hybridization reactions were incubated overnight at 56°C and then digested with RNAs A/T1 and proteinase K. Protected fragments were precipitated and separated using a 6% acrylamide Tris-borate EDTA (TBE)-urea gel and then visualized by autoradiography. Autoradiograms were scanned with a laser densitometer (Molecular Dynamics, Sunnyvale, CA)
Immunoprecipitation and immunoblotting
To analyze protein by immunoblotting of cultured cell lysates, cells (ECs and K562) were washed twice with ice-cold PBS containing 1 mM sodium orthovanadate and 1 mM sodium fluoride and were then lysed in 100 l cold RIPA lysis buffer (PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 10 g/ml leupeptin, 1 mM sodium orthovanadate). Cell lysates were clarified by centrifugation at 10,000 ϫ g for 15 min, and protein concentrations of the supernatant were determined by using a Bio-Rad assay kit (Bio-Rad, Hercules, CA). Lysates were prepared for SDS-PAGE by adding an equal volume of 2ϫ SDS-PAGE sample buffer (100 mM Tris-Cl (pH 6.8), 200 mM DTT, 4% SDS, 0.2% bromphenol blue, 20% glycerol) and heating the mixture in a boiling water bath for 3 min. Aliquots (10 g) of cell lysate were resolved by SDS-PAGE using 8% acrylamide gels and a Tris-glycine electrophoresis buffer system (25 mM Tris, 250 mM glycine, 0.1% SDS, pH 8.3), and separated proteins were transferred to a polyvinylidene difluoride membrane by electrophoresis (Immobilon P, Millipore, Bedford, MA). Membranes were incubated with blocking solution containing 5% nonfat dry milk in Tris-buffered saline-Tween (TBST) (10 mM Tris-HCl (pH 8.0), 0.150 mM NaCl, 0.05% Tween 20) at room temperature for 30 min followed by incubation with TBST containing the indicated Ab overnight at 4°C. Membranes were washed and incubated with a suitable HRP-conjugated detecting reagent (Jackson ImmunoResearch, West Grove, PA), and HRP activity was detected using an enhanced chemiluminescence (ECL) kit according to the manufacturer's instructions (Pierce, Rockford, IL). Autoradiograms were scanned by laser densitometry.
For immunoprecipitation before immunoblotting of gp130, 500 g of total cell lysate were precleared by incubation with 4 g rabbit IgG for 90 min on rotator at room temperature, followed by addition of 50 l GammaBind G-Sepharose beads (Pharmacia, Piscataway, NJ) with continual incubation on a rotator at room temperature for an additional 90 min. The beads were removed from the precleared lysates by centrifugation. To form specific immune complexes, 4 g anti-gp130 Ab were added to the precleared lysate which was then incubated for 90 min on a rotator at room temperature. To collect specific immune complexes, 50 l GammaBind G-Sepharose beads were added, and the sample was incubated on a rotator at 4°C overnight at which time beads were collected by centrifugation at 13,000 ϫ g for 1 min. The beads containing immune complexes were washed five times with PBS. The immune complexes were solubilized from the beads by addition of 1ϫ SDS-PAGE sample buffer and heated in a boiling water bath for 5 min. Aliquots were resolved by SDS-PAGE and immunoblotted for total gp130 and for phosphotyrosine residues, as described above.
Indirect immunofluorescence and FACS analysis
After treatment with cytokines, HUVECs were washed with HBSS and incubated for 1 min with trypsin-EDTA. Detached cells were collected and washed twice with ice-cold PBS containing 1% BSA and were incubated with specific primary mAb (either anti-E-selectin, anti-ICAM-1, or FITCconjugated anti-class I MHC) for 30 min at 4°C. Replicate aliquots were incubated with nonbinding isotype control mAb. Labeled cells were washed twice with PBS-1% BSA and were fixed with 2% paraformaldehyde before being analyzed. In the case of E-selectin and ICAM-1, cells were incubated with a FITC-conjugated goat anti-mouse Ab for 30 min on ice followed by washing twice with PBS-1% BSA before fixation. After fixation, cells were analyzed by FACS using a FACSort and Lysis II software (Becton Dickinson, San Jose, CA). Corrected mean fluorescence values was calculated as follows. For each treatment, the mean fluorescence value for the isotype-matched nonbinding control Ab was subtracted from the mean fluorescence value for the specific Ab.
Transfection and promoter reporter gene assays
Transient transfection of HUVECs were performed using a DEAE-dextran protocol as described previously (34) . Cells were transfected with both a B-luciferase promoter reporter gene, which contains two B sites from Ig enhancer (35) , and a constitutively active ␤-galactosidase expression construct (Promega, Madison, WI). Cell lysates were assayed for luciferase and ␤-galactosidase activities using the Promega reporter assay system (Promega). Luciferase activity was measured using a Berthold (Schwarzwald, Germany) model LB9501 luminometer, and ␤-galactosidase activity was determined by measuring absorbance at 420 nm using a spectrophotometer (Dynatech Laboratories, Easton, MA). Luciferase values in relative light units were normalized to ␤-galactosidase units to control for transfection efficiency.
C-mediated lysis
Target HUVECs were grown in 96-well plates to confluence and incubated with 20 M calcein-AM (Molecular Probes, Eugene, OR) in Medium 199 and 5 mM HEPES for 30 min at 37°C. The medium was replaced by complete EC growth medium, and cells were rested overnight. IL-11 in media or media alone were added for an addition of 6 h, after which cells were washed twice with Medium 199 containing 5% FBS, 5 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. Where indicated, 20 g/ml cycloheximide were included during the incubation with IL-11. To initiate cytotoxicity, cells were incubated with anticlass I MHC mAb (W6/32) for 30 min at 37°C. Baby rabbit C was then added at the indicated dilutions. To measure the extent of lysis after 1 h, supernatant was removed and transferred into a flat-bottom 96-well plate and released calcein was quantitated using a fluorescence multiwell plate reader (Cytofluor 2, PerSeptive Biosystems, Cambridge, MA; excitation wavelength, 485 nm; emission wavelength, 530 nm). Replicate wells were incubated with lysis buffer (50 mM sodium borate, 0.1% Triton X-100, pH 9.0) to determine maximum release or without C treatment to determine spontaneous release. Percent specific lysis was calculated as [(sample release Ϫ spontaneous release)/(maximal release Ϫ spontaneous release)] ϫ 100%. Spontaneous release was generally Ͻ25%. 
Generation of allospecific CTLs and CTL killing assay
Alloreactive class I-restricted CD8 ϩ T cells clones were produced as described elsewhere from peripheral blood CD8 ϩ T cells (36, 37) . To determine percent lysis, target HUVECs were loaded with calcein as described above and incubated overnight. IL-11 in media or media alone were added either overnight or 6 h before assay, after which cells were washed twice with Medium 199 containing 5% FBS, 5 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin. Where indicated, the MEK-1 inhibitor PD98059 or vehicle control was added 90 min before adding IL-11. Effector CTL cells were added in a total volume of 150 l/well at varying E:T ratios. In some experiments, 1 g/ml PHA (Sigma) was added to potentiate killing by lectin bridging. Replicate wells were incubated with lysis buffer (50 mM sodium borate, 0.1% Triton X-100, pH 9.0) to determine maximum release or with media alone to determine spontaneous release. After 4 h incubation at 37°C, released calcein was measured as described above. Percent specific lysis was calculated as described above. Spontaneous release was generally Ͻ25%.
Results
HUVECs express IL-11R␣
The functional receptor for IL-11 is a heterodimer composed of a signal transduction subunit, gp130, and a specific ligand-binding receptor component called IL-11R␣ (18) . HUVECs have previously been reported to express gp130 and respond to leptin (38) and oncostatin M (39 -42), two cytokines that utilize the gp130 signal transducer. We used an RNase protection assay to assess the presence of IL-11R␣ mRNA in HUVECs. A human myeloid cell line, K562, was used as a positive control because these cells express IL-11R␣ (43) . As shown in Fig. 1A , both HUVECs and K562 cells express mRNA for IL-11R␣. In contrast, IL-11R␣ mRNA was not detected in CACO-2 cells which are unresponsive to IL-11.
To assess the presence of IL-11R␣-chain protein in HUVECs we performed an immunoblot using three newly generated anti-IL-11R␣ mAbs. As shown in Fig. 1B , we detected a single major immunoreactive species in K562 cells and in HUVECs with apparent molecular mass of ϳ80 kDa. The same results were obtained with the other two mAbs (data not shown). The RNase protection assay and immunoblot indicated that HUVECs constitutively express IL-11R␣ mRNA and protein, respectively.
IL-11 causes tyrosine phosphorylation of gp130 in HUVECs
Binding of IL-11 to IL-11R␣ is necessary, although not sufficient for signal transduction. Previous studies have indicated that IL-11 utilizes JAK-induced tyrosine phosphorylation of gp130 to initiate signal transduction (18, 20) . HUVECs express gp130 and use it to transduce signals in response to an oncostatin M (40, 44, 45) or leptin (38) , two other IL-6 families of cytokines. We were unable to detect IL-11-induced tyrosine phosphorylation of gp130 by immunoblot of HUVECs lysates, although oncostatin M response could be detected by this approach (data not shown). To increase the sensitivity of the assay, we immunoprecipitated gp130 before immunoblotting with phosphotyrosine Ab. In this experiment, HUVECs were stimulated with either IL-11 or oncostatin M for 2 or 10 min, and lysed. The lysates were immunoprecipitated with gp130 Ab, and the anti-gp130 immunoprecipitates were subjected to SDS-PAGE followed by immunoblotting with Abs to phosphotyrosine (Fig. 2) . In the absence of stimulation, HUVECs express no detectable tyrosine phosphorylation of gp130. However, tyrosine phosphorylation of gp130 was reproducibly detected after 2 or 10 min of stimulation with IL-11. Oncostatin M, used as a positive control, was a more potent inducer of gp130 phosphorylation than IL-11.
IL-11 induces tyrosine phosphorylation of STAT3 and STAT1
Cytokines that signal through gp130 typically cause JAK-mediated tyrosine phosphorylation of STAT3 and, to a lesser extent, of STAT1 (22, 28) . Therefore, we used immunoblotting to determine whether IL-11 induces tyrosine phosphorylation of STAT3 and STAT1 in HUVECs. In these experiments, the specific antiphospho-STAT Abs we used only detect phosphorylation that occurs on the specific tyrosine residues involved in JAK-mediated activation of STAT dimerization, and thus immunoreactivity can be used to infer STAT activation, although this cannot be directly tested without knowledge (and analysis) of a STAT3-dependent gene. No tyrosine phosphorylation of either STAT3 or STAT1 was detected in unstimulated HUVECs by immunoblot analysis using Ab to phospho-STAT3 or phospho-STAT1 (Fig. 3, control) . After 10 min of cytokine treatment, tyrosine phosphorylation of STAT3 was induced by 0.1 ng/ml IL-11 and increased, in a dose-dependent manner, to maximal levels at ϳ50 ng/ml IL-11 (Fig. 3) . IL-11 induced tyrosine phosphorylation of STAT1 only at concentrations of Ͼ10 ng/ml (Fig. 3) . Tyrosine phosphorylation of STAT1 was increased at higher concentrations of IL-11, peaking at ϳ50 ng/ml IL-11 (Fig. 3) . These experiments suggest that the threshold concentration for an IL-11 effect on STAT1 phosphorylation was Ͼ100-fold higher than for phosphorylation of STAT3, although maximal phosphorylation occurred at similar concentrations. Immunoblot analysis of the same samples with anti-STAT3 and anti-STAT1 Abs (Fig. 3) indicated that the total levels of STAT3 and STAT1 proteins, respectively, were not changed by IL-11 treatment (i.e., phosphorylated plus nonphosphorylated). In parallel control experiments, oncostatin M induced detectable tyrosine phosphorylation of STAT3 and STAT1 at 60 pg/ml and 1.5 ng/ml, respectively (Fig. 3) . These data show that IL-11 is a less potent inducer of STAT3 and STAT1 phosphorylation than is oncostatin M. Moreover, even maximal concentrations of IL-11 failed to induce levels of STAT phosphorylation observed at optimal oncostatin M levels. In other words, IL-11 is also less efficacious than oncostatin as an activator of the JAK-STAT signaling pathway in HUVECs. Nevertheless, IL-11 clearly does activate gp130/JAK/ STAT3 and STAT1 pathways in this cell type.
We next determined the time course of IL-11 actions. Increased tyrosine phosphorylation of STAT3 after addition of IL-11 was seen as early as 2.5 min and largely disappeared by 60 min (Fig.  4) . Similarly, phospho-STAT1 was detected after 2.5 min stimu-lation with IL-11 and disappeared at 40 min (Fig. 4) . Replicate gels probed for STAT3 (data not shown) and STAT1 (data not shown) indicated that there were no changes in expression of these proteins after stimulation with IL-11 over the same time interval. Interestingly, this kinetic study indicated that IL-11 acted more rapidly than oncostatin M, which did not induce detectable STAT phosphorylation until 5 min.
To be certain that IL-11-induced STAT signaling in HUVECs was due to IL-11, we assessed the phosphorylation of STAT3 by IL-11 in the presence of neutralizing Ab to IL-11. Preincubation of IL-11 with mouse mAb anti-IL-11 Ab, but not with control Ab, completely abolished IL-11-induced phosphorylation of STAT3. The same Ab had no effect on oncostatin M-induced STAT3 phosphorylation (data not shown). Unfortunately, no inhibitory anti-IL-11R␣ Ab have been identified to date, so we could not assess the role of the receptor in this response.
IL-11 activates p42 and p44 MAPK in a dose-and timedependent manner in HUVECs
In addition to activation of STAT3 and STAT1, the MAPK signaling pathway has also been reported to be activated by cytokines that signal through gp130 (15) . Specifically, IL-11 has been reported to activate both p42 and p44 MAPK in K562 cells, in monocytic leukemia U937 cells, and in 3T3-L1 adipocytes (29, 30) . To assess the potential involvement of MAPK signaling pathway in the IL-11 signal transduction in HUVECs, we determined whether IL-11 increases threonine/tyrosine phosphorylation of p42 and p44 using Ab specific for the phosphorylated forms of these enzymes. These MAPKs are continuously activated in our cultured HUVECs through the actions of serum and growth factors necessary for cell culture. Therefore, to assess an effect of IL-11 on MAPK activation, we first made the cells quiescent by removing growth factors and lowering serum levels to 1%. Under these conditions, HUVECs contain minimal phospho-p42/p44 (Fig. 5, control) . Addition of 0.3 ng/ml IL-11 caused detectable phosphorylation of p42/ p44 above background, and the level of phosphorylation increased with increasing concentration of IL-11 (Fig. 5A) . Lower concentrations of IL-11 (Ͻ0.3 ng/ml) did not cause significant phosphorylation of p42/p44 (data not shown). In time course experiments, phospho-p42/p44 was detected by 10 -15 min but decreased at 30 min and largely disappeared after 40 min of stimulation with IL-11 (Fig. 5B) . However, significant levels of phospho-p42/p44 were still detected after 40 min of stimulation with oncostatin M (1 ng/ml) (Fig. 5B) . No change in the total p42/p44 protein levels were observed on stimulation with IL-11 over this time period (Fig. 5) . These data suggest that IL-11 can activate MAPK signaling in HUVECs. In growth factor responses, the threonine/tyrosine phosphorylation of p42 and p44 MAPK is mediated by MEK-1. Both IL-11-and ECGS-induced phosphorylation of p42/p44 MAPK are comparably reduced by the MEK-1 inhibitor PD98059 in a dose-dependent manner (Fig. 6) . 7. IL-11 neither induces the degradation of IB␣ nor inhibits the effect of TNF on this response. A, HUVECs were treated with IL-11 (10 ng/ml), IL-11 (100 ng/ml), or TNF (10 U/ml) for 5 and 10 min. B, HUVECs were pretreated with media alone (control) or media containing various doses of IL-11 (as indicated). After 4 h, cells were treated with media alone or media containing 10 U/ml TNF for 15 min. Lysates were resolved on 10% SDS-PAGE and immunoblotted with specific Ab to I-B␣. Cell lysates from HUVECs pretreated with 500 and 5000 ng/ml IL-11 were run on a separate gel. Values are the results of two independent experiment with similar results. Results are quantitated by densitometry FIGURE 8. IL-11 does not inhibit TNF-mediated B-luciferase promoter-reporter gene activity. HUVECs were transiently cotransfected with B-luciferase promoter-reporter gene and a ␤-galactosidase expression construct. Cell were treated with different doses of IL-11 as indicated. After 4 h, cells were left untreated or treated with 3 U/ml TNF for 18 h. Luciferase activity was expressed as light units normalized to ␤-galactosidase activity (RLU). Data are presented as the mean Ϯ SEM of triplicates in each group from one experiment. Shown is one of the three different experiments with similar outcome.
IL-11 does not influence the proinflammatory NF-B signaling pathway in HUVECs
Many proinflammatory cytokines activate the transcription factor NF-B (46) . The activation of NF-B has also been associated with cytoprotection against TNF-induced apoptosis (47, 48) . On the other hand, part of the antiinflammatory actions of IL-11 have been attributed to inhibition of NF-B activation in LPS-treated macrophages (12) . TNF is the prototypic activator of the NF-B pathway in HUVECs, causing rapid degradation of I-B proteins (49, 50) . We initially assessed the effects of IL-11 on NF-B activation in the presence or absence of TNF by measuring the disappearance of I-B␣ by immunoblotting. As shown in Fig. 7A , IL-11 by itself, at either 10 or 100 ng/ml, did not cause degradation of I-B␣. Moreover, pretreatment of HUVECs cultures for 4 h with various doses of IL-11 did not inhibit I-B␣ degradation induced by TNF (Fig. 7B) . Consistent with these biochemical data, IL-11 at various doses did not increase the transcription of a transiently transfected B-promoter-reporter gene construct (Fig. 8) . Moreover, pretreatment with various doses of IL-11 did not inhibit activation of the B-promoter-reporter gene induced by a submaximal dose of TNF (3 U/ml) (Fig. 8) .
The TNF-induced NF-B-dependent responses in HUVECs include the up-regulation of leukocyte adhesion molecules such as E-selectin and ICAM-1 (31) . To assess whether IL-11 modulates inflammatory functions of ECs, we examined the effects of IL-11 on E-selectin and ICAM-1 expression on HUVECs using indirect immunofluorescence. IL-11 had no direct effect on E-selectin or ICAM-1 expression (Table I) . In contrast, a submaximal concentration of TNF (1 U/ml) significantly induced both E-selectin and ICAM-1 expression at 5 h (Table I) . Neither 6 h pretreatment (data not shown) nor cotreatment (Table I) with IL-11 inhibited E-selectin or ICAM-1 expression induced by TNF. a HUVECs were treated with cytokines as indicated. Surface levels of E-selectin and ICAM-1 were quantitated by indirect immunofluorescence using H4/18 and 2D5 mAb, respectively. The numbers are expressed as corrected mean fluorescence intensity (cMFI) calculated by subtracting the mean fluorescence value for isotype-matched control mAb (K16/16) from the mean fluorescence value for either H4/18 or 2D5 mAb. Results from two independent experiments are shown.
IL-11-pretreated HUVECs are partially resistant to CTL-and C-mediated cytolysis
We next assessed whether IL-11 could protect HUVECs from immune-mediated injury in two assays: killing by class I MHC-restricted allospecific CTL clones; and killing by anti-class I MHC mAb plus C. Pretreatment with IL-11 at 0.5 ng/ml was capable of partially protecting HUVECs from lysis by CTL, but pretreatment with a higher concentration of IL-11 (50 ng/ml) failed to do so (Fig. 9) . Preincubation of the IL-11 (0.5 ng/ml) with anti-IL-11 mAb, but not with control K16/16 Ab, completely inhibited the cytoprotective effect of IL-11 in this assay (data not shown). Cytoprotection is not mediated by reduction in the expression of target molecule (i.e., class I MHC) because expression of these molecule is not altered (Table II) . IL-11 pretreatment also reduced cytolysis by CTL that has been potentiated by PHA lectin bridging (Table III) . Pretreatment of HUVEC targets with the MEK-1 inhibitor PD98059 also reduced CTL-mediated killing. However, in this case, no further protection could be conferred by IL-11. These data support a link between IL-11 cytoprotection and p42/p44 MAPK activation, but this should be interpreted with caution because of the independent actions of the MEK-1 inhibitor.
Finally, we determined whether IL-11 can protect HUVECs against C-mediated lysis initiated by an anti-MHC class I mAb and baby rabbit C. Pretreatment with IL-11 at 0.5 ng/ml significantly reduced percent specific lysis induced by mAb plus 3 and 10% C (Fig. 10A) . The action of IL-11 quantitated by dye release at 1 h seems to be truly protective because it correlated with cell survival 24 h after mAb plus C treatment determined by a Hoechst staining assay (data not shown). The protective effect of IL-11 pretreatment is dependent on protein synthesis because it was not observed when cycloheximide was present during the pretreatment period (Fig. 10B) .
Discussion
The present study was undertaken to determine whether IL-11 can directly act on vascular EC to inhibit inflammation or induce cytoprotection. We found that cultured HUVECs express IL-11R␣ mRNA and protein as well as gp130 and that stimulation of HUVECs with IL-11 induced rapid phosphorylation of gp130, STAT3, STAT1, and p42/p44 MAPKs. We also found that IL-11 pretreatment can induce HUVECs to become partially resistant to injury mediated by CTL or mAb plus C. Both p42/p44 MAPK phosphorylation and protection from CTL were reduced by the MEK-1 inhibitor PD98059. However, this drug independently reduced killing; therefore, this connection must be regarded with caution. In contrast, IL-11 does not inhibit proinflammatory responses of HUVECs to TNF, such as NF-B activation or adhesion molecule expression. These data provide the first in vitro evidence of a direct cytoprotective action of IL-11 and do not support an antiinflammatory effect of this cytokine on endothelium. A similar lack of antiinflammatory effect of IL-11 was observed when LPS rather than TNF was used as stimulus for endothelial activation (K.M. and J.S.P., unpublished observations).
Functional receptor complexes for the IL-6 family of cytokines including IL-11, oncostatin M, and IL-6 share gp130 as a component critical for signal transduction (16, 17) . IL-11 binds to IL-11R␣ on the cell surface, and the IL-11/IL-11R␣ complex then associates with gp130, causing it to cluster. This is essentially the same mechanism of action that has been observed for IL-6/IL-6R signaling. Oncostatin M differs from IL-11 and IL-6 in that it directly binds to gp130 and signals through either gp130/leukemiainhibitory factor receptor ␤ or gp130/oncostatin M receptor heterodimers (51, 52) . Because gp130 is ubiquitously expressed, the FIGURE 10. IL-11-treated HUVECs acquire resistance against C-mediated cytolysis. Confluent pooled HUVECs were loaded with calcein, chased, and pretreated for 6 h without (control) or with 0.5 ng/ml IL-11 in the presence (B) or absence (A) of cycloheximide (20 g/ml). HUVECs were washed and incubated with anti-W6/32 Ab (2.5 g/ml) followed by addition of baby rabbit C at the indicated dilutions. After 1 h, supernatant was harvested and released calcein was measured. Percent specific lysis was calculated (see Materials and Methods). Maximal and spontaneous release was significantly different for cycloheximide-treated cells and controls. These values were therefore determined for the two groups separately, and sample release was normalized to these values. Data are presented as the mean Ϯ SEM of triplicates in each group from one experiment. Shown is one of the three different experiments with similar outcome. ‫,ءء‬ p Ͻ 0.01 control vs IL-11 as determined by t test. a All determinations were performed in triplicate. IL-11 (0.5 ng/ml) was added 6 h before assay and PD98059 (30 M) was added 7.5 h before assay.
responsiveness of cells to a particular cytokine of the IL-6 family is determined by the relative expression of other receptor components. Among receptors for IL-6 cytokines, endothelial cells lack IL-6R␣ (53) but express receptors for leptin (38) and oncostatin M (40, 44, 45) . EC respond to oncostatin M with activation of MAPK activity (39), IL-6 secretion (40), P-selectin (42), ICAM-1, and E-selectin synthesis (41) , and increased growth (39) . In the present study, we showed that, compared with IL-11, oncostatin M is a much stronger inducer of gp130, STAT3, STAT1, and MAPK phosphorylation in HUVECs. Oncostatin M but not IL-11 appears to activate proinflammatory functions of HUVECs (41, 42, 44) . Thus, not all gp130-signaling cytokines induce the same biological responses in EC, and some differences may relate to signal strength. We have not been able to observe cytoprotection using oncostatin M (our unpublished observation), but this may be an issue of finding a suitable concentration. The present study raises the question of how IL-11 treatment results in an injury-resistant state. The concentrations of cytokine that are protective correlate with those that activate STAT3 and p42/p44 MAPK. Because cytoprotection depends on new protein synthesis, it is reasonable to suppose that STAT3 and/or MAPK lead to transcription of a cytoprotective protein. These two signals may act coordinately; i.e., MAPK may phosphorylate STAT3 to increase its transcription factor activity. However, we have not rigorously established a causal link between these signals and cytoprotection. There are no available agents to block STAT3 signaling. The best inhibitor of MAPK activation, the MEK-1 inhibitor PD98059, does block IL-11 effects but seems to have independent actions unrelated to IL-11 signaling. It is also unclear why higher concentrations of IL-11 are not protective. Such concentrations activate STAT1, and it has been observed that STAT1 may heterodimerize with STAT3, preventing STAT3 homodimerization. Again, we cannot causally connect STAT1 activation to loss of cytoprotection. Transgenic and knockout mouse studies may be helpful in testing these hypotheses.
We have provided the first evidence of a direct cytoprotective effect of IL-11 in vitro. The responsive target cell type, namely vascular endothelium, could well be a primary site for injury in many of the processes for which IL-11 is cytoprotective. Although our focus has been on immune-mediated injury, a primary membrane action, as we have proposed to explain our data, could extend to nonimmune models of cell injury as well.
